Pfizer, Valneva remove half of participants from study of Lyme disease shot

Pfizer, Valneva remove half of participants from study of Lyme disease shot

Source: 
BioPharma Dive
snippet: 

Violations of study standards by a “third-party clinical trial site operator” prompted the partners to stop evaluating a large portion of the volunteers in their Phase 3 trial.